States that do cover GLP-1 medications for weight loss often impose additional barriers such as prior authorization requirements, step therapy (requiring patients to fail cheaper medications first), or BMI thresholds above 35 kg/m
Researchers continue to examine how activation of various melanocortin receptor subtypes influences hormonal regulation, neurotransmitter systems, and central nervous system signaling pathways
There is no validated PHQ-2 or PHQ-9 depression instrument or explicit mental-health question, no dedicated eating-disorder screen, no substance or alcohol screen, no structured allergy capture, and no broader comorbidity multi-select covering hypertension, sleep apnea, NAFLD, PCOS, or GERD
Well meet on your schedule, via video visitand you can message us in-app anytime